CLNN vs NRXP vs SAVA vs INMB vs ACAD

For growth investors, INmune Bio, Inc.

(INMB) is the stronger pick with 257. 1% revenue growth year-over-year, versus -41. 5% for Clene Inc. (CLNN). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 9x trailing P/E (50. 9x forward), making it the more compelling value choice. Analysts rate Cassava Sciences, Inc. (SAVA) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, ACADIA Pharmaceuticals Inc.

(ACAD) delivered a total return of +7. 1%, compared to -99. 1% for NRx Pharmaceuticals, Inc. (NRXP). Over 10 years, the gap is even starker: SAVA returned -19. 5% versus NRXP's -96. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ACADIA Pharmaceuticals Inc.

(ACAD) is the lower-risk stock at 1. 26β versus INmune Bio, Inc. 's 2. 45β — meaning INMB is approximately 95% more volatile than ACAD relative to the S&P 500. On balance sheet safety, ACADIA Pharmaceuticals Inc. (ACAD) carries a lower debt/equity ratio of 4% versus 4% for INmune Bio, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), INmune Bio, Inc.

(INMB) is pulling ahead at 257. 1% versus -41. 5% for Clene Inc. (CLNN). On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc. grew EPS 77. 6% year-over-year, compared to 11. 8% for INmune Bio, Inc.. Over a 3-year CAGR, ACAD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus -918. 7% for INmune Bio, Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -617. 4% for INMB. At the gross margin level — before operating expenses — INMB leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, ACADIA Pharmaceuticals Inc.

(ACAD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). INmune Bio, Inc. (INMB) carries a higher beta of 2. 45 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACAD: -22. 9%, INMB: -82. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CLNN is a small-cap quality compounder stock; NRXP is a small-cap quality compounder stock; SAVA is a small-cap quality compounder stock; INMB is a small-cap high-growth stock; ACAD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.